$151.00
-0.22
(-0.15%)
As of Sep 5, 2026, 1:48 PM EDT
Price history
Gilead Sciences (GILD) is trading down at $151.00 (-0.15%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
About Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Recent News (20)
-
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
-
McRae Industries, Inc. Dividend Declared MOUNT GILEAD, N.C., Sept. 4, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Company's Class A and Class B Common Stock payable …
-
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
-
ITOC, PTHL Investor Alert: iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) Securities Class Action Notice - Contact SueWallSt A securities class action alleges that iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) shares climbed from a $4.00 IPO price to $32.00 before collapsing approximately 95% in a single session, with the…
-
Is Gilead Sciences Stock Outperforming the S&P 500?
Is Gilead Sciences Stock Outperforming the S&P 500?
-
-
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
-
Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?
Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?
-
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?
-
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
-
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
-
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock
-
Gilead Sciences CFO Andrew Dickinson sells $415k in shares
Gilead Sciences CFO Andrew Dickinson sells $415k in shares
-
Gilead Sciences chief comm & corp aff officer sells $3.85m stock
Gilead Sciences chief comm & corp aff officer sells $3.85m stock
-
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
-
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
-
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
-
-
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the tre…
-
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager
More Health Care stocks
- ABBV AbbVie
- AMGN Amgen
- BIIB Biogen
- INCY Incyte
- MRNA Moderna
- REGN Regeneron Pharmaceuticals
- VRTX Vertex Pharmaceuticals
- A Agilent Technologies